J.P. Morgan Healthcare Conference Presentation
Investor roadmap highlights progress of key events
Execution
Pipeline
Phase III and
regulatory
decisions²
Q2 2023
Q2 and Half-year
2023 results
Full-year 2023
upgraded guidance ✓
Therapy Area
Strategy
R&D priorities
Arexvy US
> >
regulatory approval ☑
Arexvy second
season data
BELLUS Health, Inc.
acquisition
completed
SCYNEXIS, Inc.
exclusive license
completed
K
Q3 2023
Q3 and Year-to-date
2023 results
Arexvy RSV, ≥60 YOA (JP)
Arexvy, RSV, 50-59 YoA
Q4 2023
Full-year and Q4 2023
results
Performance vs BIU
20211
Full-year 2024 guidance
Apretude, HIV pre-exposure (EU)
Vocabria, HIV treatment (CN)
Ojjaara, MOMENTUM, myelofibrosis (US)
Jemperli RUBY, 1L DMMR/MSI-H EC³ (US)
>> > > > >
H1 2024
Q1 2024 results
Q2 and Half-year 2024 results
Jemperli: RUBY, IL dMMR/MSI-H
EC³ (EU)
☑
•
Ojjaara: MOMENTUM, myelofibrosis
(EU, JP)
•
Blenrep: DREAMM-7, 2L+ MM
✓
•
gepotidacin: EAGLE-1, GC
°
depemokimab: SWIFT-1/2, asthma
•
Jemperli: RUBY (Part 2), 1L EC³
☑
•
Jemperli: RUBY (Part 1) 1L OS4 EC3
°
Zejula: FIRST, IL maintenance OC
ovarian cancer
Capital
Allocation
Capital allocation
R&D and BD
priorities
TA priorities
く
> >
Full-year 2023
dividend
declaration
Roadshows
Investor
Engagement
Meet the
management,
Meet the management,
HIV
Infectious Diseases
Meet the
management,
Respiratory
Meet the management, Oncology
Medical congresses
GSK
1. June 2021 Investor Update 2. Includes phase III data readouts and regulatory decisions with the applicable geography denoted in brackets 3. Endometrial cancer
5. cholestatic pruritus in primary biliary cholangitis
•
•
H2 2024
Q3 and Year-to-date 2024 results
Full-year and Q4 2024 results
Performance vs BIU 20211
Guidance 2025
Arexvy: RSV, 50-59 YOA (US, EU, JP)
Nucala: CRSwNP (JP)
Nucala: severe asthma (CN)
depemokimab: ANCHOR-1/2,
CRSWNP
Nucala MATINEE, COPD
cobolimab: COSTAR, 2L NSCLC
Blenrep: DREAMM-8, 2L MM
Zejula: ZEAL, IL maintenance NSCLC
linerixibat: GLISTEN, PBC5
Full-year 2024 dividend declaration
4. Overall survival population
11View entire presentation